Known targets — ChEMBL curated mechanism
TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8
The experimentally established mechanism targets of Vinblastine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB4A known ✓ | P04350 | 6/20 | 1.00 |
| ▸ | TUBB known ✓ | P07437 | 6/20 | 1.00 |
| ▸ | TUBA3C known ✓ | P0DPH7 | 6/20 | 1.00 |
| ▸ | TUBA1B known ✓ | P68363 | 6/20 | 1.00 |
| ▸ | TUBA4A known ✓ | P68366 | 6/20 | 1.00 |
| ▸ | TUBB4B known ✓ | P68371 | 6/20 | 1.00 |
| ▸ | TUBB3 known ✓ | Q13509 | 6/20 | 1.00 |
| ▸ | TUBB2A known ✓ | Q13885 | 6/20 | 1.00 |
| ▸ | TUBB8 known ✓ | Q3ZCM7 | 6/20 | 1.00 |
| ▸ | TUBA3E known ✓ | Q6PEY2 | 6/20 | 1.00 |
| ▸ | TUBA1A known ✓ | Q71U36 | 6/20 | 1.00 |
| ▸ | TUBA1C known ✓ | Q9BQE3 | 6/20 | 1.00 |
| ▸ | TUBB6 known ✓ | Q9BUF5 | 6/20 | 1.00 |
| ▸ | TUBB2B known ✓ | Q9BVA1 | 6/20 | 1.00 |
| ▸ | TUBB1 known ✓ | Q9H4B7 | 6/20 | 1.00 |
| ▸ | MAPT | P10636 | 8/20 | 1.00 |
| ▸ | MEN1 | O00255 | 7/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 7/20 | 1.00 |
| ▸ | LMNA | P02545 | 6/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 6/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vinblastine SCHEMBL28131624 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ALMNATUBB4A | |
| Vinblastine SCHEMBL2923482 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ALMNATUBB4A | |
| Vinblastine SCHEMBL29357903 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ALMNATUBB4A | |
| Vinblastine SCHEMBL29879166 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ALMNATUBB4A | |
| Vinblastine SCHEMBL6340124 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ALMNATUBB4A | |
| Vinblastine SCHEMBL3550 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ALMNATUBB4A | |
| Vinblastine SCHEMBL29554704 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ALMNATUBB4A | |
| Vinblastine SCHEMBL5535862 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ALMNATUBB4A | |
| Vinblastine SCHEMBL3549 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ALMNATUBB4A | |
| Vinblastine SCHEMBL5306718 | 0.99 | MAPT (0.99) | MAPTMEN1KMT2ALMNATUBB4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119816324-A | CD25 specific antibodies and uses thereof | 美国政府(由卫生和人类服务部的部长所代表) | 2025-04-11 | — | — | CN | disclosed |
| CN-119300859-A | Activatable multispecific molecules and methods of use thereof | 西托姆克斯治疗公司 | 2025-01-10 | — | — | CN | disclosed |
| CN-118076628-A | Activatable cytokine constructs and related compositions and methods | 西托姆克斯治疗公司 | 2024-05-24 | — | — | CN | disclosed |
| US-20230287035-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF MICRORNA RELATED DISEASES | HOFFMANN-LA ROCHE INC. (US) | 2023-09-14 | — | — | US | disclosed |
| US-11512313-B2 | Functionally-interdependent shape switching nucleic acid nanoparticles | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2022-11-29 | — | — | US | disclosed |
| US-11419873-B2 | Use of sodium channel blockers for the treatment of neuropathic pain developing as a consequence of chemotherapy | WEX MEDICAL LIMITED (HK) | 2022-08-23 | — | — | US | disclosed |
| CN-114340680-A | Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy | 坦博公司 | 2022-04-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11419873-B2 | Use of sodium channel blockers for the treatment of neuropathic pain developing as a consequence of chemotherapy | SCN10A, SCN5A, SCN3A | TUBB4A 146/4885TUBB 126/4885TUBA3C 202/4885 |
| US-20230287035-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF MICRORNA RELATED DISEASES | RNASE1, EXOSC5, SNRPE | TUBB4A 2122/4885TUBB 2693/4885TUBA3C 3537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.